Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lymphoma 3Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Vomiting 1Sarcoma, Alveolar Soft Part 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Philadelphia Chromosome 1Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Nausea 1Metastatic Neuroendocrine Prostate Cancer 1Medulloblastoma 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, B-Cell 1Leukemia 1Hematologic Neoplasms 1Ependymoma 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Solid Tumors 1

Interventions

lutetium Lu 177 dotatate 34Everolimus 33lanreotide 13gallium Ga 68 dotatate 13Temozolomide 13Magnetic Resonance Spectroscopy 13Nivolumab 12pembrolizumab 11Octreotide 11Capecitabine 11177Lu-octreotide, DOTA(0)-Tyr(3)- 10cabozantinib 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9surufatinib 8Sunitinib 8Specimen Handling 7Carboplatin 7pasireotide 6amino-acid, glucose, and electrolyte solution 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5Lutetium-177 5Ipilimumab 5Fluorodeoxyglucose F18 5Etoposide 5Cisplatin 5Bevacizumab 5telotristat ethyl 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuroendocrine Tumors × Antiemetics × Clear all
NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Ipsen

Phase 1/2 Terminated
40 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡